Share
Other content recommended for you
- MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy
- Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies
- Lessons for clinical trials from natalizumab in multiple sclerosis
- Natalizumab and progressive multifocal leucoencephalopathy
- No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study
- Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy
- Cerebellar progressive multifocal leucoencephalopathy identified by the shrimp sign
- Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies
- Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy